Conference Correspondent

Danelle Johnston, MSN, RN, HON-ONN-CG, OCN, and Tricia Strusowski, RN, MS, recapped their recent presentation from the ACCC 46th Annual Meeting & Cancer Center Business Summit, in which they discussed the National Evidence-Based Oncology Navigation Metrics: Multisite Exploratory Study to Demonstrate Value and Sustainability of Navigation Programs. The study was launched in June 2018 as a collaborative effort between the Academy of Oncology Nurse & Patient Navigators (AONN+), Chartis Oncology Solutions, and the American Cancer Society (ACS).

Genetics, Genomics, and You: A Primer for Oncology Navigators

AONN+ Conference Highlights, Conference Correspondent

April 2019 Vol 10, No 4

Nurses and navigators play a crucial role in teaching patients about genetics and genomics, as well as in gathering the vital information necessary to actually carry out genetic testing and allowing patients to take control of their genetic inheritance.

What’s Hot and Trending in Oncology Care

AONN+ Conference Highlights, Conference Correspondent

April 2019 Vol 10, No 4

At the 2018 AONN+ Annual Conference, attendees heard a rapid-fire rundown of some of the most newsworthy, and sometimes controversial, topics in cancer care.

The Importance of Trust: Reaching Disparate Populations with Cancer

AONN+ Conference Highlights, Conference Correspondent

March 2019 Vol 10, No 3

Patients with cancer, even in the most “favorable” of circumstances, often face hurdles to care.

Supercharging Your Navigation Program

AONN+ Conference Highlights, Conference Correspondent

March 2019 Vol 10, No 3

Whether an oncology navigation program is just starting out or has already become a well-oiled machine, there are usually a few—or perhaps, quite a few—ways that a navigation program can potentially be improved, according to Lillie D. Shockney, RN, BS, MAS, ONN-CG, Co-Founder and Program Director of the Academy of Oncology Nurse & Patient Navigators (AONN+).

PACIFIC: Practice-Changing Trial in Stage III Unresectable NSCLC

Conference Correspondent, Highlights From IASLC

December 2018 Vol 9, No 12

The PD-L1 inhibitor durvalumab showed an overall survival benefit in patients with unresectable stage III non–small cell lung cancer (NSCLC) in the phase 3 PACIFIC trial.

Two New Therapies Active in NSCLC with EGFR/HER2 Exon 20 Mutations

Conference Correspondent, Highlights From IASLC

Best Practices in Lung Cancer – November 2018 Vol 9

Researchers are chipping away at the genetic subtypes of non–small-cell lung cancer (NSCLC).

Entrectinib Encouraging in ROS1-Positive NSCLC

Conference Correspondent, Highlights From IASLC

Best Practices in Lung Cancer – November 2018 Vol 9

Entrectinib achieved high response rates as well as durable responses in patients with ROS1-positive non–small cell lung cancer (NSCLC), including patients with brain metastases, according to a pooled analysis of phase 1 and 2 trials.

New Regimen for SCLC: Atezolizumab plus Chemotherapy

Conference Correspondent, Highlights From IASLC

Best Practices in Lung Cancer – November 2018 Vol 9

Atezolizumab combined with carboplatin/etoposide represents a new standard of care for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC), according to results from the phase 3 IMpower133 trial presented at the IASLC 19th World Conference on Lung Cancer.

Next-Generation ALK Inhibitor Prolongs Survival vs Crizotinib in ALK+ NSCLC

Conference Correspondent, Highlights From IASLC

Best Practices in Lung Cancer – November 2018 Vol 9

Brigatinib significantly prolonged survival compared with crizotinib (standard of care) as first-line therapy in patients with advanced anaplastic lymphoma kinase (ALK)-positive non–small cell lung cancer (NSCLC).

Conference Correspondent

Page 1 of 4

Connect with Us

Subscribe Today!

I'd like to receive:

Please enter your mailing address.

We Value Your Feedback! Tell Us How You Consume Content